Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced its participation in several upcoming investor virtual conferences. Key events include the Jefferies Virtual Healthcare Conference on June 4 at 10 a.m. PT, and the William Blair Virtual Growth Stock Conference and Goldman Sachs Virtual Healthcare Conference, both on June 11, at 10 a.m. PT and 12 p.m. PT, respectively. Interested participants can access live and archived webcasts on the company’s website. Adaptive Biotechnologies focuses on using the adaptive immune system to develop diagnostic and therapeutic products for various diseases.
Adaptive Biotechnologies (Nasdaq: ADPT) reported strong financial results for Q1 2020, with revenues reaching $20.9 million, a 65% increase year-over-year. Notably, clinical tests for clonoSEQ surged 75% to 3,518 tests. The company expanded its partnership with Microsoft to tackle COVID-19 diagnostics and formed a strategic alliance with Amgen for therapeutic antibody development. However, operating expenses rose to $55.5 million, leading to a net loss of $31.4 million. Due to COVID-19 uncertainty, the company withdrew its annual revenue guidance for 2020.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities Virtual Healthcare Conference on May 6, 2020. Management will present on May 13 at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. A live and archived webcast of the presentation will be accessible on the company’s website. Adaptive Biotechnologies focuses on utilizing the adaptive immune system for clinical applications in diagnosing and treating diseases, with a pipeline that includes products for cancer, autoimmune diseases, and infections.
Summary not available.